The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) is a huge mover today! The stock increased 6.28% or $1.15 on November 23, hitting $19.45. About 196,158 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 6.80% since April 22, 2016 and is downtrending. It has underperformed by 12.21% the S&P500.
The move comes after 7 months positive chart setup for the $552.29 million company. It was reported on Nov, 24 by Barchart.com. We have $20.62 PT which if reached, will make NASDAQ:ATRA worth $33.14 million more.
Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on March, 2. They expect $-0.94 EPS, down 25.33% or $0.19 from last year’s $-0.75 per share. After $-0.88 actual EPS reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 6.82% negative EPS growth.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The firm earned “Outperform” rating on Friday, October 9 by William Blair. JMP Securities maintained the shares of ATRA in a report on Tuesday, December 15 with “Market Outperform” rating. The stock has “Sell” rating given by Goldman Sachs on Thursday, September 15. The rating was initiated by JMP Securities with “Mkt Perform” on Friday, September 25. The firm earned “Sell” rating on Friday, August 19 by Citigroup. The company was reinitiated on Monday, October 24 by Jefferies. On Wednesday, September 9 the stock rating was initiated by Canaccord Genuity with “Buy”. On Tuesday, December 15 the stock rating was downgraded by Citigroup to “Sell”. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, November 18.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment decreased to 1.48 in 2016 Q2. Its down 1.88, from 3.36 in 2016Q1. The ratio is negative, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Blackrock Fund Advsrs owns 913,922 shares or 0% of their US portfolio. Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 16,420 shares. Blackrock holds 6,100 shares or 0% of its portfolio. Swiss Bancorporation last reported 0% of its portfolio in the stock. Morgan Stanley has 3,781 shares for 0% of their US portfolio. Ubs Asset Mgmt Americas has 1.15 million shares for 0.03% of their US portfolio. Bancshares Of Mellon holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 99,629 shares. Blackrock Group Inc Limited owns 5,334 shares or 0% of their US portfolio. Nationwide Fund Advsr reported 15,110 shares or 0% of all its holdings. Baupost Grp Limited Com Ma holds 1.64% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 5.36 million shares. Blackrock Institutional Tru Na holds 489,613 shares or 0% of its portfolio. Cormorant Asset Ltd Liability has invested 0.6% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Moreover, Bridger Mngmt Limited Co has 1.48% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 1.02M shares. The North Carolina-based National Bank Of America De has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Intll Grp has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA).
Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 19 sales for $2.58 million net activity. On Tuesday, November 15 Clark Mitchall G. sold $58,492 worth of the stock or 2,995 shares. Soffer Gad also sold $120,040 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, August 15. Ciechanover Isaac E. sold $214,368 worth of stock or 9,600 shares. 1,604 Atara Biotherapeutics Inc (NASDAQ:ATRA) shares with value of $32,000 were sold by Haqq Christopher. $87,325 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by MCGRATH JOHN on Tuesday, October 11. Gallagher Carol Giltner sold $22,910 worth of stock.
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Fool.com which released: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Also Marketwatch.com published the news titled: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.